Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma-Reference-Cited by-同舟云学术

Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma

Published:2020-06-10 Issue:547 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Cissé Madi Y.¹²^ORCID,Pyrdziak Samuel¹²,Firmin Nelly¹²³^ORCID,Gayte Laurie¹²,Heuillet Maud⁴⁵,Bellvert Floriant⁴⁵^ORCID,Fuentes Maryse¹²,Delpech Hélène¹²^ORCID,Riscal Romain¹²^ORCID,Arena Giuseppe¹²,Chibon Frédéric⁶,Le Gellec Sophie⁶⁷^ORCID,Maran-Gonzalez Aurélie³^ORCID,Chateau Marie-Christine³,Theillet Charles¹²,Carrere Sébastien¹²³,Portais Jean-Charles⁴⁵⁸^ORCID,Le Cam Laurent¹²^ORCID,Linares Laetitia K.¹²^ORCID

Affiliation:

1. IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.

2. Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France.

3. Institut régional du Cancer Montpellier, Montpellier F-34298, France.

4. TBI, Université de Toulouse, CNRS, INRA, INSA, Toulouse F-31400, France.

5. MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse F-31077, France.

6. INSERM UMR 1037, Centre de Recherche en Cancérologie de Toulouse, Université Paul Sabatier Toulouse-III, Toulouse F-31100, France.

7. Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse F-31100, France.

8. Université Paul Sabatier, Université de Toulouse, Toulouse F-31062, France.

Abstract

Chromatin-bound MDM2 regulates serine metabolism and nucleotide synthesis to sustain tumor growth in liposarcoma.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference45 articles.

1. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberations

2. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

3. Pharmacological therapies for Liposarcoma

4. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma

5. Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding and Therapeutic Targeting of the p53 Network;Cancers;2023-09-07

2. Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma;Cell Genomics;2023-07

3. A metabolic crosstalk between liposarcoma and muscle sustains tumor growth;2023-06-05

4. Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies;MedComm;2023-05-28

5. A Self‐Assembly Combined Nano‐Prodrug to Overcome Gemcitabine Chemo‐Resistance of Pancreatic Tumors;Advanced Functional Materials;2023-04-21